MORARI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.067
AS - Asia 428
EU - Europa 230
Totale 1.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.063
SG - Singapore 295
IT - Italia 115
CN - Cina 110
FR - Francia 49
RU - Federazione Russa 19
VN - Vietnam 16
FI - Finlandia 14
SE - Svezia 9
NL - Olanda 8
GB - Regno Unito 7
DE - Germania 5
HK - Hong Kong 4
CA - Canada 2
CR - Costa Rica 2
ES - Italia 2
IN - India 2
KZ - Kazakistan 1
RS - Serbia 1
UA - Ucraina 1
Totale 1.725
Salva come PNG Salva come JPEG
Città #
Singapore 231
Santa Clara 164
Boardman 132
Fairfield 114
Woodbridge 82
Chandler 61
Houston 52
Seattle 41
Ashburn 40
Wilmington 38
Beijing 37
Cambridge 33
Padova 32
Ann Arbor 19
Ogden 18
Dong Ket 16
San Diego 15
Milan 11
Venice 11
Helsinki 9
Medford 9
Princeton 9
Amsterdam 8
Roxbury 7
Des Moines 6
Nanjing 6
Rome 5
Hong Kong 4
Dallas 3
Trento 3
Willimantic 3
Bologna 2
Brescia 2
Catania 2
Chester 2
Florence 2
Frankfurt am Main 2
Hebei 2
London 2
Madrid 2
Mezzolombardo 2
Mira 2
Perugia 2
Phoenix 2
Ridgewood 2
Shenyang 2
Treviso 2
Verona 2
Almaty 1
Belgrade 1
Cagliari 1
Calgary 1
Catford 1
Council Bluffs 1
Dozza 1
Fuzhou 1
Guangzhou 1
Heredia 1
Hounslow 1
Jinan 1
Kharkiv 1
Langfang 1
Los Angeles 1
Milton Keynes 1
Montebelluna 1
Moscow 1
Nanchang 1
Padenghe sul Garda 1
Prescot 1
Rambouillet 1
Reggello 1
San Pedro 1
Sedilo 1
Senftenberg 1
Serra 1
Shanghai 1
Springfield 1
Strasbourg 1
Tianjin 1
Toronto 1
Wandsworth 1
Washington 1
Wuxi 1
Zhengzhou 1
Ürümqi 1
Totale 1.290
Salva come PNG Salva come JPEG
Nome #
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 145
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 138
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 116
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex 106
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 91
Role of LRRK2 in the regulation of dopamine receptor trafficking 80
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation 49
Nociceptin/orphanin FQ receptor agonists as a novel therapy for preventing levodopa-induced dyskinesia 30
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata 26
Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity 24
Early dysfunction of substantia nigra dopamine neurons in the parkinq311x mouse 24
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 22
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 21
Autophagy and LRRK2 in the Aging Brain 16
Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology 16
An innovative approach to treat levodopa-induced dyskinesia based on targeting striatal intracellular signalling. Ente finanziatore Fondazione S. Paolo 16
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 15
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease 15
Modeling Parkinson's disease in LRRK2 mice: Focus on synaptic dysfunction and the autophagylysosomal pathway 14
Progetto Telethon 2012. (Ente finanziatore Fondazione Telethon) Funzione e disfunzione a livello presinaptico di LRRK2, una proteina chinasi associata alla malattia di Parkinson 14
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 14
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 13
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 13
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 13
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices 13
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 13
NOP receptor ligands and Parkinson’s disease 13
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 13
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 13
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 12
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat-II. Evidence for a N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function 12
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 12
Development of a new toolbox for mouse PET-CT brain image analysis fully based on CT images and validation in a PD mouse model 12
Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates 11
PRIN 2010-2011. Ente finanziatore MIUR. titolo "Discinesie indotte da L-DOPA nella malattia di Parkinson: nuovi meccanismi e target molecolari" 11
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 11
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 11
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 11
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease 11
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 11
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 11
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity 11
Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo 11
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats. New insights into the role of delta receptors in parkinsonism 11
Parkinson's disease: no NOP, new hope 11
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter 11
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 10
Differential regulation of striato-nigral and striato-pallidal pathways by striatal NR2A and NR2B subunit containing receptors 10
In vitro evidence for increased facilitation of striatal acetylcholine release via pre- and postsynaptic NMDA receptors in hemiparkinsonian rats 10
Reciprocal dopamine-glutamate modulation of release in the basal ganglia 10
Dopamine D1 and D2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid 10
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 10
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 10
Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation 10
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]-D-aspartate and endogenous GABA in freely moving guinea-pigs 10
Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia 10
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 10
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 10
Modeling Parkinson’s disease in LRRK2 rodents 10
NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways 10
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 10
5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices 10
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 10
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 9
Endogenous nociceptin/orphanin FQ contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice 9
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice 9
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 9
Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism 9
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 9
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4) 9
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 9
Dopamine Transporter, PhosphoSerine129 α-Synuclein and α-Synuclein Levels in Aged LRRK2 G2019S Knock-In and Knock-Out Mice 9
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 9
Mitochondrial targeting in LRRK2-associated parkinsonism (PARK8) 9
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 8
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 8
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway 8
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 8
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 8
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 8
Nociceptin/orphanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata 8
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 8
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 8
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 8
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 8
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 8
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 8
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 7
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats 7
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 7
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 7
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 7
Neuronal vulnerability following inhibition of mitochondrial complex II: a possibile ionic mechanism for Huntington’s disease 7
Managing Parkinson's disease: moving ON with NOP 7
N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA, and glutamate levels in the dorsolateral neostriatum of the halothane-anaesthetized rat: an in vivo microdialysis study 7
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 7
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 7
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 7
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 6
Nociceptin/orphanin FQ modulates neurotransmitter release in the substantia nigra: biochemical and behavioral outcome 6
Totale 1.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.042
article - articoli 10.626
book - libri 57
conference - conferenze 0
curatela - curatele 0
other - altro 523
patent - brevetti 0
selected - selezionate 0
volume - volumi 330
Totale 23.578
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202078 0 0 0 0 0 11 20 14 18 10 5 0
2020/202193 4 1 4 3 9 3 0 6 14 17 13 19
2021/2022137 10 8 19 10 4 9 5 23 2 6 7 34
2022/202399 22 13 1 19 13 9 0 5 12 1 1 3
2023/2024447 1 6 6 26 14 10 20 134 61 9 65 95
2024/2025778 10 184 99 74 345 66 0 0 0 0 0 0
Totale 1.859